been introduced since the early 1980s to treat severe pain, particularly in cancer patients (Caraceni et al., 2012; Corli et al., 2016; O'Brien et al., 2017; World Health Organization 1986 , 1996 .
Over the last three decades, an epidemic of opioid consumption for the treatment of pain has been observed in the United States (Berterame et al., 2016; Hastie, Gilson, Maurer, & Cleary, 2014; Schuchat, Houry, & Guy, 2017) , where an increment in the misuse/abuse of these analgesics, and consequent problems of addiction, was also reported, followed by an epidemic of deaths attributed to opioid overdose (Centers for Disease Control and Prevention 2011) . From 2014 to 2015, the death rate attributed to fentanyl and synthetic opioids other than methadone increased by 72.2%; the death rate for heroin increased by 20.6% (International Narcotics Control Board 2018) .
Opioid use has also been increasing in other areas in the world, including a few European countries, Australia and New Zealand which, together with the United States, account for about 90% of total consumption of fentanyl, oxycodone and morphine worldwide (Berterame et al., 2016; Hastie et al., 2014; Shipton, Shipton, & Shipton, 2018) . However, in many other countries, especially those in low-income areas, the use of opioids remains inadequate (Duthey & Scholten, 2014; Seya, Gelders, Achara, Milani, & Scholten, 2011) . Disparities in the availability of opioid analgesics exist not only between high and low-income regions of the world, but also within high-income regions, such as Europe (Berterame et al., 2016; Hastie et al., 2014; International Narcotics Control Board 2018) . Although several studies have reported patterns in opioid use in specific European countries (Chenaf et al., 2018; Chinellato, Skaper, Giusti, & Debetto, 2011; De Conno, Ripamonti, & Brunelli, 2005; Garcia del Pozo, Carvajal, Viloria, Velasco, & Garcia del Pozo, 2008; Hamunen, Paakkari, & Kalso, 2009; Hudec, Tisonova, Foltan, & Kristova, 2013; Just, Mucke, & Bleckwenn, 2016; Krnic et al., 2015; Neutel, Skurtveit, Berg, & Sakshaug, 2014; Zin, Chen, & Knaggs, 2014) , no study has focused on the trend of opioid consumption over time and the comparison of opioid consumption across all European countries.
In order to provide a comprehensive picture of time trends and geographic variations in opioid consumption across Europe over the last three decades, we analysed data provided by International Narcotics Control Board (INCB) (International Narcotics Control Board 2018) , the United Nations (UN) body mandated to monitor the implementation of the UN convention for narcotic drugs. For comparative purpose, we also analysed data for the United States, one of the countries with the highest opioid consumption worldwide (Berterame et al., 2016; Hastie et al., 2014 ; International Narcotics Control Board 2018).
| MATERIALS AND METHODS

| Data source
In the present study, we analysed data on opioid analgesics provided by INCB (International Narcotics Control Board 2018). The INCB annually receives data from competent national authority of each country worldwide that describe the local availability of opioids, including amount legally distributed for medical and scientific purposes, estimate of country's needs, quantity of opioids destroyed, and loss during manufacture. The submission of this information is mandatory to all signatory countries of the 1961 Single Convention on Narcotic Drugs as amended by the 1972 Protocol. These data are verified by the INCB using information from export and import notifications and by asking competent national authorities clarifications on discrepancies and gaps in information.
From the INCB secretariat, we obtained data concerning the annual consumption (in kilograms) of five more frequent consumed opioid analgesics for the treatment of severe pain in Europe, that is, fentanyl, oxycodone, morphine, hydromorphone and pethidine during 1990-2016 in 42 European countries and the United States. We excluded the Republics of Macedonia and Moldova which did not provide sufficiently reliable data, and therefore considered 40 countries. Moreover, consumption of methadone and buprenorphine was not considered, since these drugs are largely used as substitutive treatment in the case of opioid dependence. Amount of opioid analgesics was also computed for European Union (EU) as a whole, defined as the 28 Member States as in January 2013. Estimates of each country's population (in million), as provided by the UN, were also obtained from the INCB secretariat.
For each country and calendar year, we calculated the consumption of the five analgesics expressed as defined daily doses for statistical purposes (s-DDD) per 1,000,000 inhabitants. S-DDD per 1,000,000 inhabitants die was computed as annual consumption of each opioid, divided by the opioid corresponding DDD (WHO Collaborating Centre for Drug Statistics Methodology (Last accessed May, 2018)), divided by 365.25, and divided by the total country's population. We also calculated the S-DDD per 1,000,000 inhabitants die for total opioids by summing up the s-DDDs per 1,000,000 inhabitants die for each of the five analgesics.
| Statistical analysis
We computed the consumption of opioid analgesics in 40 European countries in 2004-2006 and in 2014-2016 as the 3-year mean of the s-DDDs per 1,000,000 inhabitants die, in order to remove annual variations and provide more stable data; then, we calculated the per cent change between the two values.
To analyse the trends of total opioid consumption during the period 1990-2016 in 22 selected European countries (chosen on the basis of their population size and the level of opioid consumption), the EU as a whole, and the United States, we utilized the "Joinpoint Trend Analysis Software" developed by the "Surveillance, Epidemiology, and End Results Program" of the National Cancer Institute (National Cancer Institute 2018). The joinpoint regression analysis allows identifying the best-fitting points-called "joinpoints"-where a significant change in the linear slope (on a log scale) of the trend is detected. We used joinpoint regression models allowing for up to 3 joinpoints. For each of the identified trends in 1990-2016, we also computed the estimated annual per cent changes (APC) by fitting a regression line to the natural logarithm of the consumption using calendar year as a regression variable. Figure 1 . In 2014-2016, there was a high variability in opioid use across countries: indeed, in most Western and Northern European countries and in Spain, opioid use was over 10,000 s-DDD, whereas in most Southern and Eastern European countries it was below 1,000 s-DDD ( Figure 1 and Table 1 ). In almost all countries, opioid consumption showed an extensive increase between 2004-2006 and 2014-2016 , particularly in countries of Southern and Eastern Europe ( Table 1) . Consumption of opioids was unchanged or decreased only in Estonia, Finland, Luxemburg and Ukraine. Moreover, opioids use increased from 6,477 to 8,967 s-DDD (+38.4%) in the EU as a whole, and from 14,598 to 16,491 s-DDD (+13%) in the United States. Figure 2 and Table S1 display the results of the joinpoint analysis for the trends in total opioid consumption over the period 1990-2016 in 22 selected European countries, the EU as a whole, and the United States. Consumption of opioids has steadily risen since the early to mid-1990s in all countries, with the increase being generally observed until recent years in many of those countries. However, in several countries lower APCs were observed since the mid-to late 2000s, and in a few countries from Western and Northern Europe-such as Denmark, Finland, France, Ireland and Switzerland-and also in Poland, opioid consumption declined or levelled off over most recent years. Finally, in the EU as a whole, opioid consumption increased up to 2008 and levelled off since 2009 (APC = −0.5%); similarly, in the United States opioid use rose up to 2008 and declined thereafter (APC = −2.9%).
| RESULTS
| Total opioid consumption
| Consumption of single opioid analgesics
In 2014-2016, fentanyl was the most frequently consumed opioid analgesic in all European countries in terms of s-DDD. In particular, the highest consumption of fentanyl (>7,000 s-DDD) was observed in Western and Northern European countries and also in Spain; on the contrary, use of fentanyl was much limited (<2,000 s-DDD) in most of Eastern European countries ( Figure 1 and Table S2 ). Over the last 10 years, fentanyl consumption has increased in many countries, with the strongest increase observed in Southern and Eastern Europe (Table S2 ). Fentanyl consumption increased from 3,909 to 5,248 s-DDD in the EU as a whole (+34.2%), while it decreased from 8,289 to 6,652 s-DDD (−19.7%) in the United States.
In 2014-2016, consumption of oxycodone was >1,000 s-DDD in most Western and Northern European countries, while it was <300 s-DDD in Southern and Eastern European countries ( Figure 1 and Table S3 ). Oxycodone use was negligible in Albania, Belarus, Bosnia and Herzegovina, Greece, Latvia, Lithuania, Malta, Montenegro, Russia, Serbia and Ukraine. A substantial increase was observed between 2004-2006 and 2014-2016 in all countries, with a particularly strong growth in a few Eastern countries where oxycodone availability started only over the last decade (Table S3) . Consumption of oxycodone rose from 1,591 to 2,341 s-DDD (+47.2%) in the EU as a whole, and from 4,233 to 6,989 s-DDD (+65.1%) in the United States.
In 2014-2016, consumption of morphine was extremely high in Austria (5,899 s-DDD), Denmark (2,312 s-DDD) and Switzerland (1,776 s-DDD), while it was very low (<100 s-DDD) in most countries in Southern and Eastern Europe ( Figure 1 and Table S4 ). Between 2004 Between -2006 Between and 2014 Between -2016 , morphine use increased in some countries, including Austria, Denmark, Ireland, Lithuania, Poland, Romania, Slovenia, Switzerland and the UK; conversely, it declined in several other countries, such as Belgium, Czech Republic, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Portugal, Spain, Sweden and Ukraine, without a clear geographic gradient (Table S4 ). Morphine consumption increased from 653 to 775 s-DDD (+18.7%) in the EU as a whole, and from 1,502 to 1,765 s-DDD (+17.5%) in the United States.
In 2014-2016, hydromorphone was frequently used in Austria (1,828 s-DDD) and Germany (902 s-DDD), but its consumption was limited (<40 s-DDD) in the Netherlands, Hungary, Denmark, France, and the UK, and negligible in most Eastern European countries ( Figure 1 and Table S5 ). Consumption of hydromorphone increased between 2004-2006 and 2014-2016 in most countries, while it decreased in Denmark, France, Ireland, Slovenia and Sweden (Table S5 ). In the EU as a whole, hydromorphone consumption increased (Figure 1 and Table S6 ). Moreover, pethidine use was negligible in Belarus, Russia and Ukraine. Pethidine use declined over the last decade in almost all countries except a few from Southern and Eastern Europe, that is, Croatia, Italy, Lithuania, Portugal, Romania and Spain (Table S6 ). In the EU as a whole, pethidine use declined from 53 to 13 s-DDD (−74.6%), and in the United States it declined from 121 to 24 s-DDD (−79.8%). Figure 3 displays the trends in the consumption of fentanyl, oxycodone, morphine, hydromorphone, pethidine over the period 1990-2016 in the 22 selected European countries, the EU as a whole, and the United States. Trends of the fentanyl's consumption-the most frequently taken opioid in all countries-largely corresponded to those of total opioids. With reference to other opioid analgesics, consumption of oxycodone increased in most countries in Western and Northern Europe, but less in those in Southern and Eastern Europe. Consumption of morphine increased in Austria and Switzerland, while it was stable or declined in other countries. Hydromorphone use was almost stable in most countries, but increased in Austria, Czech Republic, Germany, Ireland and Portugal. Finally, consumption of pethidine was stable or slightly declining in most countries. In the EU as a whole, use of fentanyl steadily increased since the mid-1990s, whereas the increase was much limited since the mid-2000s. Oxycodone use also steadily increased, particularly since the early 2000s, although in the last few years the increase levelled off. A slight increase was also observed for morphine-again with a levelling off over the last few years-and hydromorphone, while consumption of pethidine was declining slightly during the whole period. In the United States, consumption of fentanyl and oxycodone increased since the early 1990s, but decline in consumption was observed since the mid-2000s for fentanyl and over the last few years for oxycodone. In the EU as a whole, little increase was also observed for morphine and hydromorphone, while consumption slightly declined for pethidine.
| DISCUSSION
This study shows that consumption of opioid analgesics, especially fentanyl, has sharply increased in most European countries since the early to mid-1990s. Despite this, in the mid-2010s there was still a more than 10-fold difference between the highest consumption levels in Western and Northern European countries and the lowest ones in Southern and Eastern European countries.
The increased opioid consumption in Europe reflects the efforts made since the late 1980s by the WHO and other organizations to assert the essential need of opioid analgesics for the treatment of chronic cancer and non-cancer pain (International Narcotics Control Board 2018; O'Brien et al., 2017; World Health Organization 2011) . In most Western and Northern Europe, opioid analgesics are now widely available and, in many cases, their consumption is rather high. It has been estimated that for patients in need of palliative care, morphine-equivalent level in Western Europe is eight times the estimated need, although these data cannot be extrapolated to all patients with pain (Knaul et al., 2018) . In those countries, as in the United States, a steady increase in opioid use has been reported mainly for the treatment of non-cancer pain (Chenaf et al., 2018; Just et al., 2016; Shipton et al., 2018; Werber et al., 2015; Zin et al., 2014) , although in this context the use of opioids is still controversial (Centers for Disease Control and Prevention Public Health Service US Department of Health and Human Services, 2016; Els et al., 2017) . Over the most recent years, opioid consumption has levelled off in many Western and Northern European countries and has declined in Denmark, Finland, France, Ireland, Switzerland, and the EU as a whole. This may suggest that in Western Europe, not all the factors responsible for the opioid epidemic observed in the United States are present and that the measures being implemented by governments may prevent the development of an opioid crisis.
The lower availability of opioids in Southern and Eastern Europe, as in other areas of the world, can be attributed to several barriers, such as restrictive laws and governmental regulations, fears of possible addiction, lack of adequate training and awareness among healthcare professionals, limited economic resources and restricted formulary availability of opioids (Cherny, Baselga, de Conno, & Radbruch, 2010; Berterame et al., 2016; Vranken et al., 2016; O'Brien et al., 2017; Vranken et al., 2018; ESMO (Last accessed October, 5 2018) ). Moreover, a recent investigation indicated that gross domestic product and human development index are the strongest determinants of access to opioid analgesics (Berterame et al., 2016) .
In particular, restrictive laws and regulations-mainly enacted to prevent and counter opioid abuse and diversion-may have interfered with the use of opioids for medical proposes (Berterame et al., 2016; Cherny et al., 2010; International Narcotics Control Board 2018; Vranken et al., 2016) . A recent systematic investigation of legal and regulatory barriers to opioid access in 11 countries from Southern and Eastern Europe highlighted the existence of excessively strict rules and regulations especially in Bulgaria, Estonia, Hungary, Latvia and Lithuania (Vranken et al., 2016 (Vranken et al., , 2018 . This is reflected in the lower opioid consumption in those countries, as shown by our data. Similarly, it has been reported that the | BOSETTI ET al.
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Trends in consumption of fentanyl, oxycodone, morphine, hydromorphone, pethidine in 22 selected European countries, the European Union as a whole and the United States of America over the period 1990-2016. s-DDD: defined daily doses for statistical purposes. The mean s-DDDs per 1,000,000 inhabitants die of 3-year groups was presented, in order to remove annual variations and provides the more stable data. Different scales were defined, in order to assist reading and interpretation Russian Federation has long had unnecessarily restrictive drug control regulations and practices which made the distribution of opioid analgesics extremely arduous (Clark, 2015; Ponizovsky, Pchelintsev, Marom, & Zvartau, 2012) . However, on 1 July 2016 the Russian Federation approved an action plan to improve the availability of narcotic drugs and psychotropic (Order No. 1403-r) (International Narcotics Control Board 2017) , this suggesting possible improvement in th treatment of pain in the near future. In some countries, inadequate treatment of pain may not be entirely due to the regulatory and governmental restrictions, but are more likely to be related to social, cultural, educational factors (Barry et al., 2010; Jacobsen, Moldrup, Christrup, Sjogren, & Hansen, 2010; O'Brien et al., 2017) . For example, Italy since 2010 has one of the most compliant laws (Law 38/2010) with the WHO recommendations for pain management on a European scale (Chinellato et al., 2011) ; this notwithstanding, Italy still has a lower opioid use compared with other countries of Southern Europe. Patients' concerns of possible adverse effects-mainly nausea/vomiting and constipation-along with the limited physicians' knowledge on pain management and the lack of a proper evaluation of pain at the diagnostic stage can explain the still low opioid spread in Italy (Chinellato, Terrazzani, Walley, & Giusti, 2003; Fanelli, Cherubino, & Compagnone, 2014) .
Conversely, Spain is the only country from Southern Europe which has opioid (mainly fentanyl) consumption at the level of Western and Northern European countries. This can be due to the regulation adopted in 1995 and several informative campaigns promoted since the early 2000s to facilitate the use of opioids (Garcia del Pozo et al., 2008) .
With reference to single opioid analgesics, fentanyl is the most frequent used opioid in most of Europe and increased consumption of this analgesic has largely contributed to the rises in total opioid consumption, particularly since the early 2000s. Its easy administration and patients' compliance, along with strong marketing of transdermal use, can explain such an increase (Chinellato et al., 2003; Garcia del Pozo et al., 2008; Hamunen et al., 2009; Hudec et al., 2013) .
In contrast to the United States, in Europe oxycodone consumption has modestly increased and is still much lower than that of fentanyl. Again, this can be attributed to the introduction of stricter control measures in several European nations, on account of the large number of deaths due to oxycodone overdose reported in North America (International Narcotics Control Board 2018) .
Hydromorphone use also showed a slight increase in Europe; however, in several European countries it has been only recently introduced in the market, and in most countries in Eastern Europe it is still not used. This may be due to its relatively high costs and the limited financial resources for the management of pain in those countries (De Lima, Pastrana, Radbruch, & Wenk, 2014).
Morphine is the oldest known opioid and since the late 1980s it has been indicated by the WHO as the gold standard for the treatment of moderate to severe pain (Caraceni et al., 2012; World Health Organization 1986 , 1996 . In 2016, the United States had the highest consumption of the morphine worldwide (International Narcotics Control Board 2018), twofold higher than that in the EU as a whole. Morphine use is quite limited in Europe and has declined over the last decades in many European countries, with the main exceptions of Austria and Switzerland. In Austria, morphine is used extensively for opioid substitution therapy; therefore, a significant part of the reported consumption of morphine is not related to palliative care. Reasons for the limited consumption of morphine in other countries may include the long-standing stigma, the shift from oral to other formulations, its possible side effects, as well as its low costs, that leave low earning margins for the manufacturers (Corli et al., 2016; De Conno et al., 2005) .
Pethidine use was negligible in most European countries, and if any, it further declined over the last decades. This is probably due to the fact that pethidine has a short duration of action, low potency, and peculiar toxic effects, that is, seizures, delirium and psychological effects (International Narcotics Control Board 2018) .
To the best of our knowledge, this study represents the first comprehensive analysis of opioid consumption across all Europe over the last decades. It provides a complete description of the current situation in each European country, as well as a comparison between them. In addition, for the analysis of time trends in selected European countries, we used the joinpoint analyses which allowed us to identify significant changes in trends (National Cancer Institute 2018).
The present study has also various limitations. First of all, consumption data provided by the INCB do not refer to the amount dispensed or used by patients, but rather to the amount distributed at a retail level; in a few cases, reporting of opioid use by some governments over specific years may have been late, missing or inaccurate, although, it has been possible for the INCB to revise and correct possible under or over reporting by verifying the data with the competent national authorities, in order to guarantee the reliability of the data collected; these data do not distinguish the clinical use for opioids (such as use for analgesia or anaesthesia); they do not indicate what formulations or dosages for each opioid are available within a country; and they are not an entirely accurate indicator of pain management in a country (Hamunen et al., 2008; Hastie et al., 2014) . In any case, the INCB data provide a rough measure of opioid availability within a country and have been used to identify patterns in worldwide availability of opioids for medical needs (Berterame et al., 2016; Hastie et al., 2014) . Second, we only considered five major opioid analgesics indicated for the treatment of severe pain, omitting other active substances, that is, fentanyl analogues, hydrocodone (used almost exclusively in the United States), or other recently introduced molecules, as tapentadol. Finally, s-DDD is a technical unit of measurement | BOSETTI ET al. that provides only an approximate measure of actual dose used in clinical practice, although it has been considered the best available tool for similar investigations (Hamunen et al., 2009; Berterame et al., 2016 ; WHO Collaborating Centre for Drug Statistics Methodology (Last accessed May, 2018)).
In conclusion, notwithstanding the commitment of the WHO and other organizations to guarantee to each patient the best treatment for the relief of pain (International Narcotics Control Board 2018; O'Brien et al., 2017; World Health Organization 1986 , large disparities in the availability and usage of opioid analgesics still exist across Europe. In many Southern and Eastern European there is still room for large improvements in pain treatment (Knaul et al., 2018) . Conversely, great attention should be paid in a few countries in Western and Northern Europe that display high levels of consumption, in order to avoid the risk of abuse/misuse.
